The company's lead product candidate, elamipretide, is under review for Barth syndrome and in late-stage development for primary mitochondrial myopathy and dry age-related macular degeneration as of Q1 2025. 

Stealth Bio is also evaluating a topical ophthalmic formulation of our second-generation clinical-stage candidate, bevemipretide (SBT-272), for dry age-related macular degeneration, and have a deep pipeline of novel compounds under evaluation for rare neurological and cardiac disease indications.The company is developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging

Stealth's lead candidate, elamipretide, is an opthalmically and intraveneously-delivered compound.